This protocol addresses well-differentiated gastric neuroendocrine tumor (NET) of the gastrointestinal tract. This classification is distinct from poorly differentiated neuroendocrine carcinoma (NEC) — the WHO Classification of Endocrine Organs and Digestive System formally separates these categories, and correct classification is the key criterion for this protocol.
The protocol centres on a as the primary treatment modality. The specific agent selection, eligibility criteria, and any applicable alternatives are detailed in the full structured regimen.